Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay

Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for prevention and treatment of thromboembolic diseases. Although routine monitoring will not be required, in certain situations assessment of drug level may be helpful. This study evaluated the suitability of comme...

Full description

Saved in:

Bibliographic Details
Published in:	Thrombosis and haemostasis Vol. 104; no. 6; p. 1263
Main Authors:	Barrett, Yu Chen, Wang, Zhaoqing, Frost, Charles, Shenker, Andrew
Format:	Journal Article
Language:	English
Published:	Germany 01.12.2010
Subjects:	Anticoagulants - blood Anticoagulants - therapeutic use Blood Coagulation - drug effects Blood Coagulation Tests Clinical Trials, Phase II as Topic Dose-Response Relationship, Drug Drug Monitoring - methods Factor Xa Inhibitors Humans International Normalized Ratio Isoxazoles - blood Morpholines - blood Predictive Value of Tests Prothrombin Time Pyrazoles - blood Pyrazoles - therapeutic use Pyridones - blood Pyridones - therapeutic use Reproducibility of Results Rivaroxaban Thiophenes - blood Venous Thromboembolism - blood Venous Thromboembolism - drug therapy
ISSN:	0340-6245, 2567-689X, 2567-689X
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!